Mixed-feature depression can signal bipolar risk; spot red flags and consider lurasidone or lumateperone before standard antidepressants.
|Videos|May 4, 2021
A Life Interrupted: Impact of Mood Disorders
Author(s)Susan J. Noonan, MD, MPH
What can be done when a mood disorder upends a patient's life?
Advertisement
Susan J. Noonan, MD, MPH, talks about the way mood disorders can disrupt a patient's life, as they are chronic and often do not respond readily to treatment.
Dr Noonan is a physician consultant and Certified Peer Specialist in the Department of Psychiatry at McLean Hospital and the Massachusetts General Hospital. She is the author of four books and a blog on managing depression, most recently
Advertisement
Related to this article
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.
GLP-1 drugs may quiet cravings by reshaping brain reward and satiety signals, reducing food-seeking drive and binge-like eating, while long-term effects remain unclear.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Schizo-Obsessed! Untangling the Overlap Between Obsessive Compulsive Disorder and Schizophrenia
2
Can Digital Memory Tests Detect Tau-Related Cognitive Change Before Alzheimer Disease?
3
FDA Shelves Fast-Track Drug Review Initiative
4
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
5